Research gaps from evidence-based contraception guidance: the US Medical Eligibility Criteria for Contraceptive Use, 2016, and the US Selected Practice Recommendations for Contraceptive Use, 2016

Contraception

Volumn 94, Issue 6, 2016, Pages 582-589

  Horton, Leah G ^a   Folger, Suzanne G ^a   Berry Bibee, Erin ^a   Jatlaoui, Tara C ^a   Tepper, Naomi K ^a   Curtis, Kathryn M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; GESTAGEN; PSYCHOTROPIC AGENT;

CONTRACEPTION; CONTRACEPTIVE BEHAVIOR; DEVICE SAFETY; EVIDENCE BASED PRACTICE; FEMALE; HORMONAL CONTRACEPTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; NOTE; PELVIC INFLAMMATORY DISEASE; PROGESTIN ONLY CONTRACEPTION; RISK FACTOR; TIME; UNITED STATES; UTERINE CERVICITIS; VENOUS THROMBOEMBOLISM; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; RESEARCH;

CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CONTRACEPTION; CONTRACEPTION BEHAVIOR; CONTRACEPTIVE AGENTS; EVIDENCE-BASED PRACTICE; FEMALE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RESEARCH; UNITED STATES;

EID: 84993661745     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2016.07.017     Document Type: Note

References (44)

1. [1] Centers for Disease Control and Prevention, U.S. Medical Eligability Criteria for Contraceptive Use, 2010. MMWR Morb Mortal Wkly Rep, 59(RR-4), 2010.
2. [2] Centers for Disease Control and Prevention, U.S. Selected Practice Recommendations for Contraceptive Use, 2013. MMWR Morb Mortal Wkly Rep, 62(RR-5), 2013.
3. [3] Folger, SG, Curtis, KM, Tepper, NK, Gaffield, ME, Marchbanks, PA, Guidance on medical eligibility criteria for contraceptive use: identification of research gaps. Contraception 82:1 (2010), 113–118.
4. [4] Centers for Disease Control and Prevention, Sexually transmitted disease surveillance 2014. 2015, U.S. Department of Health and Human Services, Atlanta.
5. [5] Brunham, RC, Gottlieb, SL, Paavonen, J, Pelvic inflammatory disease. N Engl J Med 372:21 (2015), 2039–2048.
6. [6] Westrom, L, Wolner-Hanssen, P, Pathogenesis of pelvic inflammatory disease. Genitourin Med 69:1 (1993), 9–17.
7. [7] Trussell, J, Contraceptive failure in the United States. Contraception 83:5 (2011), 397–404.
8. [8] ACOG practice bulletin no. 121: long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol 118:1 (2011), 184–196.
9. [9] Workowski, K, Bolan, G, Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep, 64(No. RR-3), 2015.
10. [10] Actavis Pharma Inc, Liletta prescribing information. [Parsippany, NJ], 2015.
11. [11] Bayer HealthCare Pharmaceuticals, Skyla prescribing information. [Whippany, NJ], 2000.
12. [12] Bayer HealthCare Pharmaceuticals, Mirena prescribing information. [Wayne, NJ], 2009.
13. [13] FEI Women's Health LLC, ParaGard T 380A intrauterine copper contraceptive prescribing information. [N. Tonawanda, NY], 2005.
14. [14] Eckert, LO, Thwin, SS, Hillier, SL, Kiviat, NB, Eschenbach, DA, The antimicrobial treatment of subacute endometritis: a proof of concept study. Am J Obstet Gynecol 190:2 (2004), 305–313.
15. [15] Ness, RB, Soper, DE, Holley, RL, Peipert, J, Randall, H, Sweet, RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the pelvic inflammatory disease evaluation and clinical health (PEACH) randomized trial. Am J Obstet Gynecol 186:5 (2002), 929–937.
16. [16] Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet 386:9995 (2015), 743–800.
17. [17] Hall, KS, Moreau, C, Trussell, J, Barber, J, Role of young women's depression and stress symptoms in their weekly use and nonuse of contraceptive methods. J Adolesc Health 53:2 (2013), 241–248.
18. [18] Westhoff, C, Truman, C, Kalmuss, D, Cushman, L, Davidson, A, Rulin, M, et al. Depressive symptoms and Depo-Provera. Contraception 57:4 (1998), 237–240.
19. [19] Hall, KS, Kusunoki, Y, Gatny, H, Barber, J, The risk of unintended pregnancy among young women with mental health symptoms. Soc Sci Med 100 (2014), 62–71.
20. [20] Alder, J, Fink, N, Bitzer, J, Hosli, I, Holzgreve, W, Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? A critical review of the literature. J Matern Fetal Neonatal Med 20:3 (2007), 189–209.
21. [21] Halbreich, U, The association between pregnancy processes, preterm delivery, low birth weight, and postpartum depressions-the need for interdisciplinary integration. Am J Obstet Gynecol 193:4 (2005), 1312–1322.
22. [22] Martini, J, Knappe, S, Beesdo-Baum, K, Lieb, R, Wittchen, HU, Anxiety disorders before birth and self-perceived distress during pregnancy: associations with maternal depression and obstetric, neonatal and early childhood outcomes. Early Hum Dev 86:5 (2010), 305–310.
23. [23] National Center for Health S. Health, United States, Health, United States, 2013: with special feature on prescription drugs. 2014, National Center for Health Statistics (US), Hyattsville (MD).
24. [24] Berry-Bibee, E, Kim, M-J, Simmons, K, Tepper, N, Riley, H, Pagano, P, et al. Drug interactions between hormonal contraceptives and psychotropic drugs: a systematic review. Contraception 94:6 (2016), 650–667.
25. [25] Edelbroek, PM, Zitman, FG, Knoppert-van der Klein, EA, van Putten, PM, de Wolff, FA, Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women. Clin Chim Acta 165:2–3 (1987), 177–187.
26. [26] Abernethy, DR, Greenblatt, DJ, Shader, RI, Imipramine disposition in users of oral contraceptive steroids. Clin Pharmacol Ther 35:6 (1984), 792–797.
27. [27] Food and Drug Administration, Guidance for industry. Drug interaction studies-study design, data analysis, implcations for dosing and labeling recommendations. Available from: http://wwwfdagov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/defaulthtm, 2012.
28. [28] Haslemo, T, Refsum, H, Molden, E, The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine. Br J Clin Pharmacol 71:4 (2011), 611–615.
29. [29] Lidegaard, O, Lokkegaard, E, Jensen, A, Skovlund, CW, Keiding, N, Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 366:24 (2012), 2257–2266.
30. [30] Heinemann, LA, Dinger, JC, Range of published estimates of venous thromboembolism incidence in young women. Contraception 75:5 (2007), 328–336.
31. [31] Stegeman, BH, de Bastos, M, Rosendaal, FR, van Hylckama, VA, Helmerhorst, FM, Stijnen, T, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ, 347, 2013, f5298.
32. [32] Bergendal, A, Persson, I, Odeberg, J, Sundstrom, A, Holmstrom, M, Schulman, S, et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol 124:3 (2014), 600–609.
33. [33] van Hylckama Vlieg, A, Helmerhorst, FM, Rosendaal, FR, The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 30:11 (2010), 2297–2300.
34. [34] Tepper, N, Whiteman, M, Marchbanks, P, James, A, Curtis, K, Progestin-only contraception and thromboembolism: a systematic review. Contraception 94 (2016), 678–700.
35. [35] Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case–control study. World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception. Contraception 57:5 (1998), 315–324.
36. [36] Christiansen, SC, Lijfering, WM, Helmerhorst, FM, Rosendaal, FR, Cannegieter, SC, Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event. J Thromb Haemost 8:10 (2010), 2159–2168.
37. [37] Mantha, S, Karp, R, Raghavan, V, Terrin, N, Bauer, KA, Zwicker, JI, Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ, 345, 2012, e4944.
38. [38] Lijfering, WM, Rosendaal, FR, Cannegieter, SC, Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol 149:6 (2010), 824–833.
39. [39] Alhenc-Gelas, M, Plu-Bureau, G, Guillonneau, S, Kirzin, JM, Aiach, M, Ochat, N, et al. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. J Thromb Haemost 2:9 (2004), 1594–1600.
40. [40] Chakhtoura, Z, Canonico, M, Gompel, A, Scarabin, PY, Plu-Bureau, G, Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis. J Clin Endocrinol Metab 96:4 (2011), 1169–1174.
41. [41] Kuhl, H, Effects of progestogens on haemostasis. Maturitas 24:1–2 (1996), 1–19.
42. [42] Vieira, CS, Ferriani, RA, Garcia, AA, Pintao, MC, Azevedo, GD, Gomes, MK, et al. Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. Hum Reprod 22:8 (2007), 2196–2201.
43. [43] Phillips, SJ, Tepper, NK, Kapp, N, Nanda, K, Temmerman, M, Curtis, KM, Progestogen-only contraceptive use among breastfeeding women: a systematic review. Contraception 94:3 (2016), 226–252.
44. [44] Daniels, K, Daugherty, J, Jones, J, Current contraceptive status among women aged 15–44: United States, 2011-2013. NCHS Data Brief(173), 2014, 1–8.